NasdaqGS:NVCRMedical Equipment
NovoCure (NVCR) Stock Faces Ongoing Losses As Q2 2026 EPS Narrows To $0.13 Loss
Fresh out of its Q2 2026 report, NovoCure (NVCR) posted total revenue of US$183.6 million and a basic EPS loss of US$0.13, with trailing twelve month revenue at US$699.2 million and a full year EPS loss of US$1.31. The company has seen quarterly revenue move from US$158.8 million in Q2 2025 to US$183.6 million in Q2 2026. Basic EPS losses across recent quarters have ranged from US$0.31 to US$0.62, underlining an earnings profile that remains in the red even as top line figures scale higher...